BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19834874)

  • 1. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens.
    Yagasaki H; Kobayashi K; Saitou T; Nagamine K; Mitsui Y; Mochizuki M; Kobayashi K; Cho H; Ohyama K; Amemiya S; Nakazawa S
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):195-9. PubMed ID: 19834874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with insulin glargine does not suppress serum IGF-1.
    Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG
    Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes.
    Ekström K; Salemyr J; Zachrisson I; Carlsson-Skwirut C; Ortqvist E; Bang P
    Diabetes Care; 2007 Jun; 30(6):1357-63. PubMed ID: 17372150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factors and their binding proteins in children with IDDM.
    Wacharasindhu S; Srivuthana S; Aroonparkmongkol S
    J Med Assoc Thai; 2002 Jan; 85(1):41-52. PubMed ID: 12075719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
    Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G
    Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients?
    Lindgren BF; Odar-Cederlöf I; Ericsson F; Brismar K
    Growth Regul; 1996 Sep; 6(3):137-43. PubMed ID: 8894646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased 24 h mean insulin-like growth factor binding protein-3 proteolytic activity in pubertal type 1 diabetic boys.
    Zachrisson I; Brismar K; Carlsson-Skwirut C; Dahlquist G; Wallensteen M; Bang P
    Growth Horm IGF Res; 2000 Dec; 10(6):324-31. PubMed ID: 11161963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse changes in fetal insulin-like growth factor (IGF)-1 and IGF binding protein-1 in association with higher birth weight in maternal diabetes.
    Lindsay RS; Westgate JA; Beattie J; Pattison NS; Gamble G; Mildenhall LF; Breier BH; Johnstone FD
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):322-8. PubMed ID: 17302863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance.
    Ricart W; Fernández-Real JM
    Obes Res; 2001 Oct; 9(10):631-6. PubMed ID: 11595780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C; Jung R; Hofmann U
    Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM; Daly F; Holly JM; Hughes SC; Camacho-Hübner C; Abdulla AF; Gale EA; Savage MO
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy].
    Peczyńska J; Urban M; Głowińska B; Urban B
    Pol Merkur Lekarski; 2003 Apr; 14(82):336-9. PubMed ID: 12868196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
    Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
    Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes.
    Holl RW; Teller WM; Heinze E
    Exp Clin Endocrinol Diabetes; 1996; 104(5):360-4. PubMed ID: 8957270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM.
    Kobayashi K; Amemiya S; Sawanobori E; Higashida K; Ishihara T; Kobayashi K; Kato K; Nakazawa S
    Diabetes Care; 1997 Sep; 20(9):1442-7. PubMed ID: 9283794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion.
    Hedman CA; Frystyk J; Lindström T; Oskarsson P; Arnqvist HJ
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):58-62. PubMed ID: 23865977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes.
    Attia N; Caprio S; Jones TW; Heptulla R; Holcombe J; Silver D; Sherwin RS; Tamborlane WV
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2324-8. PubMed ID: 10404797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.